| Name | Title | Contact Details |
|---|
M.L. Medical Billing is a full-service medical billing firm founded in 1985. We offer a reliable, accurate alternative to handling your billing in-house. Here's what we can do for you: Manage patient billing so you can focus on patient care. We take
Lumens is a California-based online marketplace that sells products such as LED lamps, fans and lounge chairs for individuals.
Catholic Charities of Buffalo is the most comprehensive human service provider serving all of Western New York, reaching all eight counties with 51 professionally staffed locations plus a presence in many area schools and other community sites. Catholic Charities serves 125,000 Western New Yorkers each year without regard to age, gender, race or religious affiliation. Catholic Charities offers programs that strive to empower individuals, children and families. Among them are comprehensive counseling services for all ages, basic emergency assistance and referrals including operating 9 food pantries,, child and adult behavioral health and substance use treatment, educational and workforce training programs, older adults support, relationship/marriage counseling, immigration and refugee assistance and a variety of programs focusing on family safety and stabilization. Catholic Charities is a Better Business Bureau of Upstate New York Accredited Charity and we are consistently awarded high marks from Charity Navigator.
Williams Inference Svc is one of the leading companies in the Business Services sector.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.